Cargando…
Cytoreductive Surgery plus Hyperthermic Intraperitoneal Chemotherapy for Management of Peritoneal Sarcomatosis: A Preliminary Single-Center Experience from Saudi Arabia
Aim. To report our preliminary single-center experience with cytoreductive surgery (CRS) plus hyperthermic intraperitoneal chemotherapy (HIPEC) for management of peritoneal sarcomatosis (PS). Methods. Eleven patients were retrospectively analyzed for perioperative details. Results. Cytoreduction com...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4860243/ https://www.ncbi.nlm.nih.gov/pubmed/27212941 http://dx.doi.org/10.1155/2016/6567473 |
_version_ | 1782431038530650112 |
---|---|
author | Abu-Zaid, Ahmed Azzam, Ayman Abuzaid, Mohammed Elhassan, Tusneem Albadawi, Naryman Alkhatib, Lynn AlOmar, Osama Alsuhaibani, Abdullah Amin, Tarek Al-Badawi, Ismail A. |
author_facet | Abu-Zaid, Ahmed Azzam, Ayman Abuzaid, Mohammed Elhassan, Tusneem Albadawi, Naryman Alkhatib, Lynn AlOmar, Osama Alsuhaibani, Abdullah Amin, Tarek Al-Badawi, Ismail A. |
author_sort | Abu-Zaid, Ahmed |
collection | PubMed |
description | Aim. To report our preliminary single-center experience with cytoreductive surgery (CRS) plus hyperthermic intraperitoneal chemotherapy (HIPEC) for management of peritoneal sarcomatosis (PS). Methods. Eleven patients were retrospectively analyzed for perioperative details. Results. Cytoreduction completeness (CC-0/1) was achieved in all patients with median peritoneal cancer index (PCI) of 14 ± 8.9 (range: 3–29). Combination cisplatin + doxorubicin HIPEC chemotherapy was used in 6 patients. Five patients received intraoperative radiation therapy (IORT). The median operative time, estimated blood loss, and hospital stay were 8 ± 1.4 hours (range: 6–10), 1000 ± 250 mL (range: 700–3850), and 11 ± 2.4 days (range: 7–15), respectively. Major postoperative Clavien-Dindo grade III/IV complications occurred in 1 patient and none developed HIPEC chemotherapy-related toxicities. The median overall survival (OS) and disease-free survival (DFS) after CRS + HIPEC were 28.3 ± 3.2 and 18.0 ± 4.0 months, respectively. The median follow-up time was 12 months (range: 6–33). Univariate analysis of several prognostic factors (age, gender, PS presentation/pathology, CC, PCI, HIPEC chemotherapy, and IORT) did not demonstrate statistically significant differences of OS and DFS. Conclusion. CRS + HIPEC appear to be feasible, safe, and offer survival oncological benefits. However, definitive conclusions cannot be deduced. |
format | Online Article Text |
id | pubmed-4860243 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Hindawi Publishing Corporation |
record_format | MEDLINE/PubMed |
spelling | pubmed-48602432016-05-22 Cytoreductive Surgery plus Hyperthermic Intraperitoneal Chemotherapy for Management of Peritoneal Sarcomatosis: A Preliminary Single-Center Experience from Saudi Arabia Abu-Zaid, Ahmed Azzam, Ayman Abuzaid, Mohammed Elhassan, Tusneem Albadawi, Naryman Alkhatib, Lynn AlOmar, Osama Alsuhaibani, Abdullah Amin, Tarek Al-Badawi, Ismail A. Gastroenterol Res Pract Clinical Study Aim. To report our preliminary single-center experience with cytoreductive surgery (CRS) plus hyperthermic intraperitoneal chemotherapy (HIPEC) for management of peritoneal sarcomatosis (PS). Methods. Eleven patients were retrospectively analyzed for perioperative details. Results. Cytoreduction completeness (CC-0/1) was achieved in all patients with median peritoneal cancer index (PCI) of 14 ± 8.9 (range: 3–29). Combination cisplatin + doxorubicin HIPEC chemotherapy was used in 6 patients. Five patients received intraoperative radiation therapy (IORT). The median operative time, estimated blood loss, and hospital stay were 8 ± 1.4 hours (range: 6–10), 1000 ± 250 mL (range: 700–3850), and 11 ± 2.4 days (range: 7–15), respectively. Major postoperative Clavien-Dindo grade III/IV complications occurred in 1 patient and none developed HIPEC chemotherapy-related toxicities. The median overall survival (OS) and disease-free survival (DFS) after CRS + HIPEC were 28.3 ± 3.2 and 18.0 ± 4.0 months, respectively. The median follow-up time was 12 months (range: 6–33). Univariate analysis of several prognostic factors (age, gender, PS presentation/pathology, CC, PCI, HIPEC chemotherapy, and IORT) did not demonstrate statistically significant differences of OS and DFS. Conclusion. CRS + HIPEC appear to be feasible, safe, and offer survival oncological benefits. However, definitive conclusions cannot be deduced. Hindawi Publishing Corporation 2016 2016-04-24 /pmc/articles/PMC4860243/ /pubmed/27212941 http://dx.doi.org/10.1155/2016/6567473 Text en Copyright © 2016 Ahmed Abu-Zaid et al. https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Clinical Study Abu-Zaid, Ahmed Azzam, Ayman Abuzaid, Mohammed Elhassan, Tusneem Albadawi, Naryman Alkhatib, Lynn AlOmar, Osama Alsuhaibani, Abdullah Amin, Tarek Al-Badawi, Ismail A. Cytoreductive Surgery plus Hyperthermic Intraperitoneal Chemotherapy for Management of Peritoneal Sarcomatosis: A Preliminary Single-Center Experience from Saudi Arabia |
title | Cytoreductive Surgery plus Hyperthermic Intraperitoneal Chemotherapy for Management of Peritoneal Sarcomatosis: A Preliminary Single-Center Experience from Saudi Arabia |
title_full | Cytoreductive Surgery plus Hyperthermic Intraperitoneal Chemotherapy for Management of Peritoneal Sarcomatosis: A Preliminary Single-Center Experience from Saudi Arabia |
title_fullStr | Cytoreductive Surgery plus Hyperthermic Intraperitoneal Chemotherapy for Management of Peritoneal Sarcomatosis: A Preliminary Single-Center Experience from Saudi Arabia |
title_full_unstemmed | Cytoreductive Surgery plus Hyperthermic Intraperitoneal Chemotherapy for Management of Peritoneal Sarcomatosis: A Preliminary Single-Center Experience from Saudi Arabia |
title_short | Cytoreductive Surgery plus Hyperthermic Intraperitoneal Chemotherapy for Management of Peritoneal Sarcomatosis: A Preliminary Single-Center Experience from Saudi Arabia |
title_sort | cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy for management of peritoneal sarcomatosis: a preliminary single-center experience from saudi arabia |
topic | Clinical Study |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4860243/ https://www.ncbi.nlm.nih.gov/pubmed/27212941 http://dx.doi.org/10.1155/2016/6567473 |
work_keys_str_mv | AT abuzaidahmed cytoreductivesurgeryplushyperthermicintraperitonealchemotherapyformanagementofperitonealsarcomatosisapreliminarysinglecenterexperiencefromsaudiarabia AT azzamayman cytoreductivesurgeryplushyperthermicintraperitonealchemotherapyformanagementofperitonealsarcomatosisapreliminarysinglecenterexperiencefromsaudiarabia AT abuzaidmohammed cytoreductivesurgeryplushyperthermicintraperitonealchemotherapyformanagementofperitonealsarcomatosisapreliminarysinglecenterexperiencefromsaudiarabia AT elhassantusneem cytoreductivesurgeryplushyperthermicintraperitonealchemotherapyformanagementofperitonealsarcomatosisapreliminarysinglecenterexperiencefromsaudiarabia AT albadawinaryman cytoreductivesurgeryplushyperthermicintraperitonealchemotherapyformanagementofperitonealsarcomatosisapreliminarysinglecenterexperiencefromsaudiarabia AT alkhatiblynn cytoreductivesurgeryplushyperthermicintraperitonealchemotherapyformanagementofperitonealsarcomatosisapreliminarysinglecenterexperiencefromsaudiarabia AT alomarosama cytoreductivesurgeryplushyperthermicintraperitonealchemotherapyformanagementofperitonealsarcomatosisapreliminarysinglecenterexperiencefromsaudiarabia AT alsuhaibaniabdullah cytoreductivesurgeryplushyperthermicintraperitonealchemotherapyformanagementofperitonealsarcomatosisapreliminarysinglecenterexperiencefromsaudiarabia AT amintarek cytoreductivesurgeryplushyperthermicintraperitonealchemotherapyformanagementofperitonealsarcomatosisapreliminarysinglecenterexperiencefromsaudiarabia AT albadawiismaila cytoreductivesurgeryplushyperthermicintraperitonealchemotherapyformanagementofperitonealsarcomatosisapreliminarysinglecenterexperiencefromsaudiarabia |